Company news

Pharma Mar SA news in 2025

Pharma Mar SA's news releases, calls and decks from 2025, newest first.

View company

PharmaMar presents at ASCO that the Zepzelca®(lurbinectedin) and atezolizumab (Tecentriq®) combination significantly improves survival as first-line maintenance therapy for extensive-stage small cell lung cancer

June 3, 2025

Annual Report (ANNUAL REPORT 2024)

April 24, 2025

Separate Financial Statements (SEPARATE FINANCIAL STATEMENTS 2024)

April 24, 2025

Annual Report (ANNUAL REPORT PHARMAMAR 1)

March 18, 2025

Decks in 2025